Heart Failure
SGLT2 Inhibitors (Farxiga / Jardiance)
SGLT2 inhibitors have been tested in six major trials with more than 35,000 patients. The bars show how much each drug reduced key risks compared to placebo. Teal bars show death and kidney outcomes.
This is a free, plain-language patient education guide written by Rias Ali, MD, FACC, a board-certified interventional cardiologist. Every guide is grounded in current peer-reviewed evidence and major society guidelines, organized in a way patients can actually use during a visit.
Download the SGLT2 Inhibitors (Farxiga / Jardiance) guide
What's inside this guide
- Plain-language explanation of sglt2 inhibitors (farxiga / jardiance)
- Why it matters and what the major risks are
- Treatment options with risks, benefits, and alternatives
- Common misconceptions clarified
- Lifestyle and self-care advice
- Specific warning signs — when to call us, when to call 911
- Sources used to build the guide (peer-reviewed and society guidelines)